Abstract:Background. MicroRNAs (miRNAs) have been found in virtually all body fluids and used successfully as biomarkers for various diseases. Evidence indicates that miRNAs have important roles in IgA nephropathy (IgAN), a major cause of renal failure. In this study, we looked for differentially expressed miRNAs in IgAN and further evaluated the correlations between candidate miRNAs and the severity of IgAN.Methods. Microarray and RT-qRCR (real-time quantitative polymerase chain reaction) were sequentially used to screen and further verify miRNA expression profiles in urinary sediments of IgAN patients in two independent cohorts. The screening cohort consisted of 32 urine samples from18 patients with IgAN, 4 patients with MN (membranous nephropathy), 4 patients with MCD (minimal changes disease) and 6 healthy subjects; the validation cohort consisted of 102 IgAN patients, 41 MN patients, 27 MCD patients and 34 healthy subjects. The renal pathological lesions of patients with IgAN were evaluated according to Lee's grading system and Oxford classification.Results. At the screening phase, significance analysis of microarrays analysis showed that no miRNA was differentially expressed in the IgAN group compared to all control groups. But IgAN grade I-II and III subgroups (according to Lee's grading system) shared dysregulation of two miRNAs (miR-3613-3p and miR-4668-5p). At the validation phase, RT-qPCR results showed that urinary level of miR-3613-3p was significantly lower in IgAN than that in MN, MCD and healthy controls (0.47, 0.44 and 0.24 folds, respectively, all P < 0.01 by Mann-Whitney U test); urinary level of miR-4668-5p was also significantly lower in IgAN than that in healthy controls (0.49 fold, P < 0.01). Significant correlations were found between urinary levels of miR-3613-3p with 24-hour urinary protein excretion (Spearman r = 0.50, P = 0.034), eGFR (estimated glomerular filtration rate) (r = -0.48, P = 0.043) and Lee's grades (r = 0.57, P = 0.014). Similarly, miR-4668-5p was significantly correlated with eGFR (r = -0.50, P = 0.034) and Lee's grades (r = 0.57, P = 0.013). For segmental glomerulosclerosis according to Oxford classification, patients scored as S0 had significantly lower levels of urinary miR-3613-3p and miR-4668-5p than those scored as S1 (0.41 and 0.43 folds, respectively, all P < 0.05).Conclusions. The expression profile of miRNAs was significantly altered in urinary sediments from patients with IgAN. Urinary expression of miR-3613-3p was down-regulated in patients with IgAN. Moreover, urinary levels of both miR-3613-3p and miR-4668-5p were correlated with disease severity. Further studies are needed to explore the roles of miR-3613-3p and miR-4668-5p in the pathogenesis and progression of IgA nephropathy.

Altered Serum Metabolic Profile in Patients with IgA Nephropathy.

Integrated Proteomics and Metabolomics to Study IgA Nephropathy on Early Stage and Identification of Biomarkers

Itraq-Based Comparative Proteomics Analysis Reveals Specific Urinary Biomarkers for Various Kidney Diseases.

Clinical and Pathology Features of IgA Nephropathy with Active Tubular Interstitial Lesions

Microbiome and metabolome analysis to clarify the interaction between the urine microbiota and serum metabolites in Chinese patients with immunoglobulin A nephropathy

Serum Proteomic Analysis by Nanoflow LC-MS/MS-Based Proteomics in IgA Chronic Kidney Disease

Identification of a Novel Interplay Between Intestinal Bacteria and Metabolites in Chinese Patients with IgA Nephropathy Via Integrated Microbiome and Metabolome Approaches

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis

Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology

LC-MS/MS based metabolomics and proteomics reveal candidate biomarkers and molecular mechanism of early IgA nephropathy

Metabolic Dysfunctions of Intestinal Fatty Acids and Tryptophan Reveal Immuno-Inflammatory Response Activation in IgA Nephropathy

Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients

Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy

The Effects of Specific Gut Microbiota and Metabolites on IgA Nephropathy—Based on Mendelian Randomization and Clinical Validation

Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis

Higher Serum Angiotensinogen is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes Analysis

Comprehensive Analysis of Aberrantly Expressed Profiles of Mrna and Its Relationship with Serum Galactose-Deficient IgA1 Level in IgA Nephropathy

Profiling and Initial Validation of Urinary Micrornas As Biomarkers in IgA Nephropathy

Mass spectrometry-based screening identifies circulating immunoglobulinA–α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy

Analysis of the differential urinary protein profile in IgA nephropathy patients of Uygur ethnicity